Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers

This study is currently recruiting participants.
Verified April 2013 by The University of Texas Health Science Center at San Antonio
Sponsor:
Collaborator:
Information provided by (Responsible Party):
The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier:
NCT00223483
First received: September 13, 2005
Last updated: April 2, 2013
Last verified: April 2013

September 13, 2005
April 2, 2013
March 2005
March 2015   (final data collection date for primary outcome measure)
Repository collection of plasma and serum for future analysis. [ Time Frame: 12 years ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00223483 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers
Identification and Analysis of Immunomodulatory Molecules From Leukocytes in Patients With Hematologic Disorders and Healthy Volunteers

This research study goal is to analyze the plasma and the cells that make up part of the immune system. We want to learn how the plasma and cells work. These may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms.

This research study goal is to analyze the plasma and the cells that make up part of the immune system. These cells, called white cells or leukocytes, are present in blood. We want to learn how these cells work to prevent infection and how they respond after an infection occurs. We also want to study certain molecules present on the plasma, on or in these cells, and the genetic material that allows these molecules to be made. These molecules may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms. This study may increase our understanding of a variety of diseases including infections such as HIV, allergic diseases such as asthma, joint diseases such as rheumatoid arthritis, certain cancers, and the rejection process that sometimes occurs after transplantation of an organ.

Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Whole blood, serum, white cells

Non-Probability Sample

Primary care clinic and community samples

  • Hematologic Diseases
  • Healthy Volunteers
Genetic: Isolation of genomic DNA
One time blood draw
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1000
March 2015
March 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Must be able to give blood
  • Must be able to give informed consent
  • Signed, written informed consent

Exclusion Criteria:

  • Individuals with a history severe anemia, inadequate venous access, severe blood or coagulation disorders.
  • Pregnant women are excluded because it is a unique immunotolerant state and will alter the profile of immunomodulatory molecules.
Both
18 Years and older
Yes
Contact: Juan J Toro, MD 210-617-5300 ext 16777 juantoro2@va.gov
United States
 
NCT00223483
HSC20040268H
No
The University of Texas Health Science Center at San Antonio
The University of Texas Health Science Center at San Antonio
Department of Veterans Affairs
Study Director: Cesar O Freytes, MD The University of Texas Health Science Center at San Antonio
The University of Texas Health Science Center at San Antonio
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP